Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma: BCMA-Directed Therapies

Despite treatment advances, multiple myeloma remains incurable, with many patients relapsing or becoming resistant to treatment. Therefore, there is an urgent need for the continual development of novel and effective therapies. B-cell maturation antigen (BCMA)-directed therapies have presented a new avenue for patients with relapsed/refractory multiple myeloma (RRMM), as the different modalities have shown to be highly effective and tolerable. With an expansion to the treatment arsenal, it is important for oncology teams to stay abreast of the latest practice-changing data and guideline recommendations to improve patient outcomes.

Join us in this 3-part educational Med Table Talk^® on Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM): BCMA-Directed Therapies as our experts from the US and Western Europe have a candid conversation about the role of BCMA in MM, the clinical implications of new and emerging BCMA-directed therapies, and practical strategies for treatment sequencing.